Degarelix versus Goserelin plus Bicalutamide Therapy for Lower Urinary Tract Symptom Relief, Prostate Volume Reduction and Quality of Life Improvement in Men with Prostate Cancer: A Systematic Review and Meta-Analysis

2014 ◽  
Vol 93 (2) ◽  
pp. 152-159 ◽  
Author(s):  
Yuanshan Cui ◽  
Huantao Zong ◽  
Huilei Yan ◽  
Nan Li ◽  
Yong Zhang
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Systematic Review ◽  
Lower Urinary Tract ◽  
Prostate Volume ◽  
Meta Analysis ◽  
Symptom Relief ◽  
Life Improvement ◽  
Lower Urinary

Physical exercise and quality of life in patients with prostate cancer: systematic review and meta-analysis

2021 ◽  
Author(s):  
Júlio Araújo Rendeiro ◽  
Cesar Augusto Medeiros Paiva Rodrigues ◽  
Letícia de Barros Rocha ◽  
Rodrigo Santiago Barbosa Rocha ◽  
Marianne Lucena da Silva ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Systematic Review ◽  
Physical Exercise ◽  
Meta Analysis

scholarly journals LOWER URINARY TRACT AND BOWEL SYMPTOMS PREDICT QUALITY OF LIFE IN GAY AND BISEXUAL PROSTATE CANCER SURVIVORS

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S490-S491
Author(s):  
Kristine M Talley ◽  
Elizabeth Polter ◽  
Benjamin D Capistrant ◽  
William G West ◽  
Badrinath Konety ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Urinary Tract ◽  
Lower Urinary Tract ◽  
Common Symptom ◽  
Bowel Symptoms ◽  
Treatment Type ◽  
And Bisexual ◽  
Lower Urinary

Abstract Little is known about disparities in prostate cancer survivorship experienced by gay and bisexual men (GBM). However, early evidence suggests GBM may experience worse urinary and bowel symptoms than heterosexual men. This cross-sectional Internet-based survey describes the prevalence of lower urinary tract (LUTS) and bowel symptoms and their associations with physical and mental health related quality of life (QOL) in GBM treated for prostate cancer. This study enrolled 193 men who identified as gay or bisexual and had received prostate cancer treatment. The Expanded Prostate Cancer Index Composite instrument measured LUTS and bowel symptoms. The MOS SF-12 measured physical and mental QOL. Participants had a mean age of 63.4 years, were 5.6 years past treatment, and were treated with prostatectomy (52%), radiation (19%), or combined or systemic treatment (29%). The most common symptoms were nocturia (77%), urinary frequency (67%), urinary leakage (59%), bowel urgency (45%), bowel frequency (35%), and watery bowel movements (34%). Mean scores were 81.4±19.2 for urinary function, 74.5±20.7 for urinary bother, 88.9±12.1 for bowel function, 84.5±16.3 for bowel bother, 52.5±8.8 for physical QOL, and 46.0±11.4 for mental QOL. In multivariable models adjusted for age, race, treatment type, and time since diagnosis, urinary bother was associated with worse physical QOL (Adjusted Mean Difference (AMD): 0.11, 95%CI: 0.02-0.21), and bowel bother was associated with worse mental QOL (AMD: 0.23, 95%CI: 0.05-0.42). LUTS and bowel symptoms were common. Symptom bother rather than function predicted QOL. Understanding these disparities will help tailor treatments for this underserved population.

Sign in / Sign up

Export Citation Format

Share Document